Biomarker development in the context of urologic cancers
about
Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniquesCIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients.Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer PatientsComparison of isolation platforms for detection of circulating renal cell carcinoma cells.
P2860
Biomarker development in the context of urologic cancers
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Biomarker development in the context of urologic cancers
@ast
Biomarker development in the context of urologic cancers
@en
type
label
Biomarker development in the context of urologic cancers
@ast
Biomarker development in the context of urologic cancers
@en
prefLabel
Biomarker development in the context of urologic cancers
@ast
Biomarker development in the context of urologic cancers
@en
P2093
P2860
P1433
P1476
Biomarker development in the context of urologic cancers
@en
P2093
Caroline C Sigman
Gary J Kelloff
Howard I Scher
P2860
P304
P356
10.1016/J.UROLONC.2015.01.007
P577
2015-03-05T00:00:00Z